FTC injunction blocks Edwards' JenaValve acquisition; Edwards raises FY2026 EPS guidance to $2.90-$3.05

Edwards Lifesciences Corp

US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.
Edwards revises FY2026 adjusted EPS guidance upward to $2.90-$3.05 from $2.80-$2.95.
Edwards disagrees with ruling, remains committed to AR therapy; advancing SOJOURN valve and JOURNEY trial.
Additional updates expected at Q4 earnings call in February.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.